Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank71
5Y CAGR-26.2%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

5Y CAGR
-26.2%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202536.01%
202423.29%
202361.83%
2022-19.81%
2021439.98%
2020164.92%
2019-72.57%
2018-136.93%
2017366.07%
2016-35.87%